Every 8-K that Core Laboratories Inc. (CLB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CLB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLB filings page.
Core Laboratories Inc. (CLB) reports that director Kwaku Temeng has resigned from the Board of Directors, effective October 1, 2026. He currently serves as Chairman of the Nominating Committee and as a member of the Compensation Committee.
Temeng informed the Board verbally on August 19, 2026 and confirmed by letter on August 25, 2026. His letter states that the resignation is due to a disagreement with the Board regarding the Company’s strategic direction and certain governance practices. The Board believes his primary disagreement involves how succession planning is being conducted and concerns about the Company’s research priorities. His resignation letter is included as an exhibit, and the Company notes his more than five years of service and contributions.
Core Laboratories Inc. reported second‑quarter 2026 revenue of $124,609,000, up 2.3% sequentially and down 4.3% year‑over‑year. GAAP operating income was $9,151,000 and diluted EPS attributable to Core was $0.13, while EPS excluding specified items was $0.11. Reservoir Description revenue was $78,747,000 with 5% operating margin, pressured by Middle East and Russia‑Ukraine disruptions, while Production Enhancement revenue was $45,862,000 with 12% operating margin and 15% sequential growth.
Core generated free cash flow of $3,122,000 on net cash from operations of $7,809,000 and $4,687,000 of operational capital expenditures. It repurchased 214,712 shares for approximately $2,700,000 and ended June 30, 2026 with net debt of $93,600,000 and a leverage ratio of 1.30. The Board declared a quarterly dividend of $0.01 per share payable August 31, 2026.
Management projects third‑quarter 2026 revenue of $128,500,000–$135,500,000, operating income of $10,500,000–$15,000,000 and EPS of $0.12–$0.20, assuming a 25% tax rate. Return on invested capital for the last four quarters was 8.3%, reflecting the company’s asset‑light model and emphasis on proprietary technologies and international growth despite geopolitical headwinds.
Core Laboratories Inc. reported that shareholders approved all three proposals at its Annual Meeting held on May 12, 2026 in Houston, Texas. Two Class I directors, Harvey Klingensmith and Curtis Anastasio, were re-elected, each receiving strong majority support.
Shareholders also ratified the appointment of KPMG LLP as independent registered public accountant for the year ending December 31, 2026. In addition, an advisory vote approved the company’s executive compensation program, including the philosophy, policies and procedures described in its Compensation Discussion and Analysis.
Core Laboratories Inc. reported first quarter 2026 revenue of $121.8 million, down 11.9% from the prior quarter and 1.4% from a year earlier. GAAP operating income fell to $1.9 million and the company posted a GAAP net loss of $0.8 million, or $0.02 per diluted share.
Excluding stock compensation, write-downs and foreign exchange, operating income was $6.6 million and EPS was $0.06, both sharply lower than recent periods. Reservoir Description revenue was $81.9 million and Production Enhancement revenue was $39.9 million, with results pressured by Middle East conflict and severe weather in North America and Europe.
Free cash flow was $0.5 million on $4.0 million of operating cash flow and $3.4 million of operational capital spending. Net debt was $94.2 million with a leverage ratio of 1.20, and return on invested capital was 9.1%. The company repurchased 51,781 shares for about $0.9 million and declared a $0.01 quarterly dividend, payable June 1, 2026 to shareholders of record May 11, 2026. Second quarter 2026 revenue is projected at $123–$131 million and EPS at $0.06–$0.12.
Core Laboratories Inc. updated its outlook for first quarter 2026, warning that revenue and earnings will fall below guidance issued on February 4, 2026 due to the escalating Middle East conflict. The company now expects revenue between $119,000,000 and $123,000,000, with operating income ex-items of $5,700,000 to $7,100,000. Earnings per share ex-items are projected at $0.05 to $0.07. Client-driven project delays, travel constraints, supply-chain disruptions and damage to regional oil infrastructure are pressuring activity, especially in Reservoir Description, while Production Enhancement is less affected but facing shipment delays. Core plans to discuss results on an April 30, 2026 earnings call following an April 29, 2026 release.
Core Laboratories Inc. is filing an amended current report to correct income tax accounting in its previously released 2025 results. Estimated income tax expense for the quarter and year ended December 31, 2025 increased by $4.2 million, reducing net income by the same amount and lowering diluted earnings per share by $0.09 per share. The change stems mainly from updated analyses of deferred tax assets and liabilities and the tax treatment of insurance proceeds from a fire at the company’s Aberdeen, U.K. facility. Core also corrected immaterial prior-period items, including a $5.6 million write-off of older income tax receivables and a $4.7 million misclassification between income tax receivable and deferred tax liabilities. The company states these tax adjustments do not affect consolidated revenue, operating income, income before tax, or cash from operations previously reported in its earnings release.
Core Laboratories Inc. changed its bylaws to make it easier for shareholders to approve major corporate actions. On February 27, 2026, the board adopted First Amended and Restated Bylaws that lower the voting threshold in Section 2.11 for certain shareholder approvals, including merger and change in control transactions, from a 66-2/3% supermajority vote to a simple majority of 50% plus one vote. This means fewer shares are now required to approve these significant transactions. The full text of the amended bylaws is provided as an exhibit to the filing.
Core Laboratories Inc. filed a current report stating it issued a press release with its financial results for the fourth quarter of 2025 and the year ended December 31, 2025. The company also announced a quarterly cash dividend of $0.01 per share of common stock.
The dividend will be paid on March 9, 2026 to shareholders of record on February 16, 2026. The related press release is furnished as an exhibit and is not treated as filed or incorporated by reference into other securities law filings unless specifically referenced.
Core Laboratories Inc. (CLB) reported that it issued a press release announcing its financial results for the third quarter of 2025. The company also declared a quarterly cash dividend of $0.01 per share, payable to shareholders of record on November 3, 2025 and payable on November 24, 2025.
The press release is furnished as Exhibit 99.1. The information is being furnished under Items 2.02 and 7.01 and is not deemed filed for liability purposes.